CRASH-3 design. CRASH-3 was designed to further investigate using tranexamic acid for patients with traumatic brain injury. This study utilized the following inclusion criteria: Enrollment within <3 hours of injury. Either Glasgow Coma Scale <13 or intracranial hemorrhage on CT scan. No major extracranial bleeding.